Forte Biosciences (FBRX) Common Equity (2016 - 2026)

Forte Biosciences (FBRX) has 11 years of Common Equity data on file, last reported at $42.1 million in Q1 2026.

• On a quarterly basis, Common Equity rose 9.56% year-over-year to $42.1 million in Q1 2026; TTM through Mar 2026 was $42.1 million, a 9.56% increase from a year earlier, with the FY2025 full-year figure at $61.0 million, up 16.22% from the prior year.
• Common Equity for Q1 2026 stood at $42.1 million, down from $61.0 million in the prior quarter.
• Over the last five years, Common Equity for FBRX reached as high as $98.6 million in Q2 2025 and fell as low as $9.4 million in Q3 2024.
• Historically, Common Equity has averaged $42.7 million across 5 years, with a median of $38.8 million in 2022.
• Across the five-year window, Common Equity sank 76.82% in 2024 and jumped 797.9% in 2025, its largest moves.
• Year by year, Common Equity stood at $38.8 million in 2022, then dropped by 9.03% to $35.3 million in 2023, then surged by 48.61% to $52.5 million in 2024, then rose by 16.22% to $61.0 million in 2025, then tumbled by 30.97% to $42.1 million in 2026.
• Per Business Quant data, the three most recent Common Equity figures were $42.1 million in Q1 2026, $61.0 million in Q4 2025, and $84.1 million in Q3 2025.